Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were acquired at a price of $2.2828 each, totaling $45,656.

Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

Paul Andrea, Chief Legal Officer at Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently reported a sale of company stock ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis ...

Pomerantz LLP is investigating claims on behalf of investors of  Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...

The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...